Abstract Cyclin-dependent kinase 4 (CDK4) and CDK6 are critical mediators of cellular
transition into S phase and are important for the initiation, growth and survival of many …

Ductal carcinoma in situ (DCIS) represents pre-invasive breast carcinoma. In untreated
cases, 25–60% DCIS progress to invasive ductal carcinoma (IDC). The challenge lies in …

Background In a previous analysis of this phase 3 trial, first-line ribociclib plus letrozole
resulted in significantly longer progression-free survival than letrozole alone among …

Background An earlier analysis of this phase 3 trial showed that the addition of a cyclin-
dependent kinase 4 and 6 (CDK4/6) inhibitor to endocrine therapy provided a greater …

The development and approval of cyclin-dependent kinase (CDK) 4 and 6 inhibitors for
hormone receptor-positive and human epidermal growth factor receptor 2 (HER2)-negative …

Purpose This phase III study evaluated ribociclib plus fulvestrant in patients with hormone
receptor–positive/human epidermal growth factor receptor 2–negative advanced breast …

Cancer is characterized by uncontrolled tumour cell proliferation resulting from aberrant
activity of various cell cycle proteins. Therefore, cell cycle regulators are considered …

Blockade of the cyclin-dependent kinase 4 and 6 pathway has been shown to be effective in
the treatment of hormone receptor-positive advanced breast cancer (ABC). We report the …

Background In the PALOMA-3 study, the combination of the CDK4 and CDK6 inhibitor
palbociclib and fulvestrant was associated with significant improvements in progression-free …

Cellular senescence, a process that imposes permanent proliferative arrest on cells in
response to various stressors, has emerged as a potentially important contributor to aging …